If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 51 - 60 of 295
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC
Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer
Protocol No
ECOG-EA3161
Categories
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintena
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma.
Protocol No
FH-COG-ARST2031
A Phase 1/2, Open-Label Study of PD-1 Knockout Tumor-Infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Protocol No
IOVANCE-IOV-GM1-201
Categories
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
The purpose of this part of this study is to compare the effects, good and/or bad, of the standard treatment (radiation therapy and cisplatin) with one of the experimental treatments chosen from the first part of the study (either radiation therapy and docetaxel or radiation therapy, cetuximab, and docetaxel) to find out which is better.
Protocol No
RTOG-1216
Categories
A Phase 1/2, Multicenter, Open-label, Single Arm, Dose Escalation and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) Not Eligible for Intensive
A Phase 1/2, Study of Gilteritinib, Venetoclax and Azacitidine in Patients with AML
Protocol No
ASTELLAS-2215-CL-0203
Categories
A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Comparing drugs for advanced non-small cell lung cancer with EGFR and MET gene changes
Protocol No
SWOG-S1900G
Categories
Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
Protocol No
ALLIANCE-A022001-PNETS
Categories
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Protocol No
ALLIANCE-A022101-ERASUR
Categories
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
Testing Efficacy of Triplet Vs Doublet Chemo in Locally Advanced Rectal Cancer
Protocol No
ALLIANCE-A022104-JANUS
Categories
PD-Inhibitor (Nivolumab) and Ipilimumab followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
This study is being done to answer the following question: Can we prolong life for patients with
advanced kidney cancer, by adding a drug called cabozantinib to another treatment after
receiving the standard treatment?
advanced kidney cancer, by adding a drug called cabozantinib to another treatment after
receiving the standard treatment?
Protocol No
ALLIANCE-A031704-PDIGREE
Categories